Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

Journal of Lipid Research

Volumn 57, Issue 3, 2016, Pages 340-351

  Graham, Mark J ^a   Viney, Nick ^a   Crooke, Rosanne M ^a   Tsimikas, Sotirios ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Aortic stenosis; Atherosclerosis; Myocardial infarction

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A; LIPOPROTEIN A; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; AORTA STENOSIS; AORTA VALVE STENOSIS; APOA GENE; ARTERY CALCIFICATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; EXON; GENE EXPRESSION REGULATION; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LPA GENE; MACACA FASCICULARIS; MALE; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; TREATMENT OUTCOME; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); DEFICIENCY; GENETICS; HUMAN;

ANIMALS; APOLIPOPROTEINS A; CLINICAL TRIALS AS TOPIC; HUMANS; LIPOPROTEIN(A); OLIGONUCLEOTIDES, ANTISENSE;

EID: 84963934456     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R052258     Document Type: Review

References (62)

1. Kronenberg , F. , and G. Utermann . 2013 . Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273 : 6 - 30
2. McLean , J. W. , J. E. Tomlinson , W. J. Kuang , D. L. Eaton , E. Y. Chen , G. M. Fless , A. M. Scanu , and R. M. Lawn . 1987 . cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature . 330 : 132 - 137 .
3. Boerwinkle , E. , C. C. Leffert , J. Lin , C. Lackner , G. Chiesa , and H. H. Hobbs . 1992 . Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90 : 52 - 60 .
4. Erqou , S. , S. Kaptoge , P. L. Perry , E. Di Angelantonio , A. Thompson , I. R. White , S. M. Marcovina , R. Collins , S. G. Thompson , and J. Danesh . 2009 . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA . 302 : 412 - 423 .
5. Clarke , R. , J. F. Peden , J. C. Hopewell , T. Kyriakou , A. Goel , S. C. Heath , S. Parish , S. Barlera , M. G. Franzosi , S. Rust , et al .; PROCARDIS Consortium . 2009 . Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361 : 2518 - 2528 .
6. Thanassoulis , G. , C. Y. Campbell , D. S. Owens , J. G. Smith , A. V. Smith , G. M. Peloso , K. F. Kerr , S. Pechlivanis , M. J. Budoff , T. B. Harris , et al . 2013 . Genetic associations with valvular calcifi cation and aortic stenosis. N. Engl. J. Med. 368 : 503 - 512 .
7. Kamstrup , P. R. , M. Benn , A. Tybjaerg-Hansen , and B. G. Nordestgaard . 2008 . Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation . 117 : 176 - 184 .
8. Kamstrup , P. R. , A. Tybjaerg-Hansen , and B. G. Nordestgaard . 2014 . Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J. Am. Coll. Cardiol. 63 : 470 - 477 .
9. Capoulade , R. , K. L. Chan , C. Yeang , P. Mathieu , Y. Bossé , J. G. Dumesnil , J. W. Tam , K. K. Teo , A. Mahmut , X. Yang , et al . 2015 . Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J. Am. Coll. Cardiol. 66 : 1236 - 1246 .
10. Dubé , J. B. , M. B. Boffa , R. A. Hegele , and M. L. Koschinsky . 2012 . Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23 : 133 - 140 .
11. Bergmark C. , DewanA. , OrsoniA. , MerkiE. , MillerE.R. , ShinM.J. , BinderC.J. , HorkkoS. , KraussR.M. , ChapmanM.J. , et al. . 2008 . A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasmaJ. Lipid Res.49 : 2230-2239
12. Merki E. , GrahamM. , TalebA. , LeibundgutG. , YangX. , MillerE.R. , FuW. , MullickA.E. , LeeR. , WilleitP. , et al. . 2011 . Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic miceJ. Am. Coll. Cardiol.57 : 1611-1621
13. Spence , J. D. , and M. L. Koschinsky . 2012 . Mechanisms of lipoprotein(a) pathogenicity. Arterioscler. Thromb. Vasc. Biol. 32 : 1550 - 1551 .
14. Van Dijk R.A. , KolodgieF. , RavandiA. , LeibundgutG. , HuP.P. , PrasadA. , MahmudE. , DennisE. , CurtissL.K. , WitztumJ.L. , et al. . 2012 . Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesionsJ. Lipid Res.53 : 2773-2790
15. Leibundgut G. , ScipioneC. , YinH. , SchneiderM. , BoffaM.B. , GreenS. , YangX. , DennisE.A. , WitztumJ.L. , KoschinskyM.L. , et al. . 2013 . Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a) J. Lipid Res.54 : 2815-2830
16. Wiesner P. , TafelmeierM. , ChittkaD. , ChoiS.H. , ZhangL. , ByunY.S. , AlmazanF. , YangX. , IqbalN. , ChowdhuryP. , et al. . 2013 . MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma J. Lipid Res.54 : 1877-1883
17. Henry , S. P. , R. S. Geary , R. Yu , and A. A. Levin . 2001 . Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr. Opin. Investig. Drugs . 2 : 1444 - 1449 .
18. Crooke , S. T. 2004 . Progress in antisense technology. Annu. Rev. Med. 55 : 61 - 95 .
19. Tsimikas , S. , N. J. Viney , S. G. Hughes , W. Singleton , M. J. Graham , B. F. Baker , J. L. Burkey , Q. Yang , S. M. Marcovina , R. S. Geary , et al . 2015 . Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet . 386 : 1472 - 1483 .
20. Geary , R. S. , D. Norris , R. Yu , and C. F. Bennett . 2015 . Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87 : 46 - 51 .
21. Geary , R. S. , B. F. Baker , and S. T. Crooke . 2015 . Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(® )): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin. Pharmacokinet. 54 : 133 - 146 .
22. Yu , R. Z. , J. S. Grundy , and R. S. Geary . 2013 . Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin. Drug Metab. Toxicol. 9 : 169 - 182 .
23. Crooke , S. T. , and R. S. Geary . 2013 . Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br. J. Clin. Pharmacol. 76 : 269 - 276 .
24. Gaudet D. , BrissonD. , TremblayK. , AlexanderV.J. , SingletonW. , HughesS.G. , GearyR.S. , BakerB.F. , GrahamM.J. , CrookeR.M. , et al. . 2014 . Targeting APOC3 in the familial chylomicronemia syndrome. N. EnglJ. Med.371 : 2200-2206
25. Büller , H. R. , C. Bethune , S. Bhanot , D. Gailani , B. P. Monia , G. E. askob , A. Segers , P. Verhamme , and J. I. Weitz ; FXI-ASO Investigators . 2015 . Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. ed. 372 : 232 - 240.
26. Gaudet D. , AlexanderV.J. , BakerB.F. , BrissonD. , TremblayK. , SingletonW. , GearyR.S. , HughesS.G. , VineyN.J. , GrahamM.J. , et al. . 2015 . Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N. EnglJ. Med.373 : 438-447
27. Geary , R. S. 2009 . Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metab. Toxicol. 5 : 381 - 391 .
28. Morishita , R. , S. Yamada , K. Yamamoto , N. Tomita , I. Kida , I. Sakurabayashi , A. Kikuchi , Y. Kaneda , R. Lawn , J. Higaki , et al . 1998 . Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. Circulation . 98 : 1898 - 1904 .
29. Sniderman , A. D. , S. Tsimikas , and S. Fazio . 2014 . The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J. Am. Coll. Cardiol. 63 : 1935 - 1947 .
30. Merki , E. , M. J. Graham , A. E. Mullick , E. R. Miller , R. M. Crooke , R. E. Pitas , J. L. Witztum , and S. Tsimikas . 2008 . Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation . 118 : 743 - 753 .
31. Raal , F. J. , R. D. Santos , D. J. Blom , A. D. Marais , M. J. Charng , W. C. Cromwell , R. H. Lachmann , D. Gaudet , J. L. Tan , S. Chasan-Taber , et al . 2010 . Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, doubleblind, placebo-controlled trial. Lancet . 375 : 998 - 1006 .
32. McGowan , M. P. , J. C. Tardif , R. Ceska , L. J. Burgess , H. Soran , I. Gouni-Berthold , G. Wagener , and S. Chasan-Taber . 2012 . Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One . 7 : e49006 .
33. Stein , E. A. , R. Dufour , C. Gagne , D. Gaudet , C. East , J. M. Donovan , W. Chin , D. L. Tribble , and M. McGowan . 2012 . Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation . 126 : 2283 - 2292 .
34. Thomas , G. S. , W. C. Cromwell , S. Ali , W. Chin , J. D. Flaim , and M. Davidson . 2013 . Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62 : 2178 - 2184 .
35. Santos , R. D. , F. J. Raal , A. L. Catapano , J. L. Witztum , E. Steinhagen-Thiessen , and S. Tsimikas . 2015 . Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler. Thromb. Vasc. Biol. 35 : 689 - 699 .
36. Schneider M. , WitztumJ.L. , YoungS.G. , LudwigE.H. , MillerE.R. , TsimikasS. , CurtissL.K. , MarcovinaS.M. , TaylorJ.M. , LawnR.M. , et al. . 2005 . High-level lipoprotein [a] expression in transgenic mice: Evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteinsJ. Lipid Res. 46 : 769-778
37. Kiechl , S. , J. Willeit , M. Mayr , B. Viehweider , M. Oberhollenzer , F. Kronenberg , C. J. Wiedermann , S. Oberthaler , Q. Xu , J. L. Witztum , et al . 2007 . Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27 : 1788 - 1795 .
38. Tsimikas , S. , Z. Mallat , P. J. Talmud , J. J. Kastelein , N. J. Wareham , M. S. Sandhu , E. R. Miller , J. Benessiano , A. Tedgui , J. L. Witztum , et al . 2010 . Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol. 56 : 946 - 955 .
39. Tsimikas , S. , P. Willeit , J. Willeit , P. Santer , M. Mayr , Q. Xu , A. Mayr , J. L. Witztum , and S. Kiechl . 2012 . Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J. Am. Coll. Cardiol. 60 : 2218 - 2229 .
40. Ravandi A. , LeibundgutG. , HungM.Y. , PatelM. , HutchinsP.M. , MurphyR.C. , PrasadA. , MahmudE. , MillerY.I. , DennisE.A. , et al. . 2014 . Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans J. Am. Coll. Cardiol.63 : 1961-1971
41. Tsimikas , S. , G. W. Duff , P. B. Berger , J. Rogus , K. Huttner , P. Clopton , E. Brilakis , K. S. Kornman , and J. L. Witztum . 2014 . Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J. Am. Coll. Cardiol. 63 : 1724 - 1734 .
42. Byun , Y. S. , J. H. Lee , B. J. Arsenault , X. Yang , W. Bao , D. DeMicco , R. Laskey , J. L. Witztum , S. Tsimikas , and T. N. T. T. Investigators . 2015 . Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J. Am. Coll. Cardiol. 65 : 1286 - 1295 .
43. Frazer , K. A. , G. Narla , J. L. Zhang , and E. M. Rubin . 1995 . The apolipoprotein(a) gene is regulated by sex hormones and acutephase inducers in YAC transgenic mice. Nat. Genet. 9 : 424 - 431 .
44. Azrolan , N. , D. Gavish , and J. L. Breslow . 1991 . Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model. J. Biol. Chem. 266 : 13866 - 13872 .
45. Gavish , D. , N. Azrolan , and J. L. Breslow . 1989 . Plasma lp(a) concentration is inversely correlated with the ratio of Kringle IV/ Kringle V encoding domains in the apo(a) gene. J. Clin. Invest. 84 : 2021 - 2027 .
46. Yeang , C. , J. L. Witztum , and S. Tsimikas . 2015 . 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr. Opin. Lipidol. 26 : 169 - 178 .
47. Stein , E. A. , R. P. Giugliano , M. J. Koren , F. J. Raal , E. M. Roth , R. Weiss , D. Sullivan , S. M. Wasserman , R. Somaratne , J. B. Kim , et al . 2014 . Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur. Heart J. 35 : 2249 - 2259 .
48. Raal , F. J. , R. P. Giugliano , M. S. Sabatine , M. J. Koren , G. Langslet , H. Bays , D. Blom , M. Eriksson , R. Dent , S. M. Wasserman , et al . 2014 . Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63 : 1278 - 1288 .
49. Cannon C.P. , ShahS. , DanskyH.M. , DavidsonM. , BrintonE.A. , GottoA.M. , StepanavageM. , LiuS.X. , GibbonsP. , AshrafT.B. , et al. . 2010 . Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl J. Med. 363 : 2406-2415
50. Hovingh , G. K. , J. J. Kastelein , S. J. van Deventer , P. Round , J. Ford , D. Saleheen , D. J. Rader , H. B. Brewer , and P. J. Barter . 2015 . Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet . 386 : 452 - 460 .
51. Safarova , M. S. , M. V. Ezhov , O. I. Afanasieva , G. A. Konovalov , and S. N. Pokrovsky . 2015 . Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis. J. Clin. Apher. 30 : 193 - 195 .
52. Khan , T. Z. , A. Pottle , D. J. Pennell , and M. S. Barbir . 2015 . The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial. Atheroscler. Suppl. 18 : 103 - 108 .
53. Schettler , V. J. , C. L. Neumann , C. Peter , T. Zimmermann , U. Julius , E. Roeseler , F. Heigl , W. Ramlow , and H. Blume ; Scientific Board of GLAR for the German Apheresis Working Group . 2015 . First data from the German Lipoprotein Apheresis Registry (GLAR). Atheroscler. Suppl. 18 : 41 - 44 .
54. Groβ , E. , B. Hohenstein , and U. Julius . 2015 . Effects of lipoprotein apheresis on the lipoprotein(a) levels in the long run. Atheroscler. Suppl. 18 : 226 - 232 .
55. Heigl , F. , R. Hettich , N. Lotz , H. Reeg , T. Pflederer , D. Osterkorn , K. Osterkorn , and R. Klingel . 2015 . Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. Clin. Res. Cardiol. Suppl. 10 : 8 - 13 .
56. Leebmann , J. , E. Roeseler , U. Julius , F. Heigl , R. Spitthoever , D. Heutling , P. Breitenberger , W. Maerz , W. Lehmacher , A. Heibges , et al . 2013 . Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation . 128 : 2567 - 2576 .
57. Tsimikas , S. , E. S. Brilakis , E. R. Miller , J. P. McConnell , R. J. Lennon , K. S. Kornman , J. L. Witztum , and P. B. Berger . 2005 . Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353 : 46 - 57 .
58. Goldenberg , N. A. , T. J. Bernard , J. Hillhouse , J. Armstrong-Wells , J. Galinkin , R. Knapp-Clevenger , L. Jacobson , S. M. Marcovina , and M. J. Manco-Johnson . 2013 . Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica . 98 : 802 - 807 .
59. Prakash , T. P. , M. J. Graham , J. Yu , R. Carty , A. Low , A. Chappell , K. Schmidt , C. Zhao , M. Aghajan , H. F. Murray , et al . 2014 . Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42 : 8796 - 8807 .
60. Park , E. I. , Y. Mi , C. Unverzagt , H. J. Gabius , and J. U. Baenziger . 2005 . The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc. Proc. Natl. Acad. Sci. USA . 102 : 17125 - 17129 .
61. Stockert , R. J. 1995 . The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. 75 : 591 - 609 .
62. Albers , J. J. , M. L. Koschinsky , and S. M. Marcovina . 2007 . Evidence mounts for a role of the kidney in lipoprotein(a) catabolism. Kidney Int. 71 : 961 - 962 .